Conference paper

Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine Hagedorn insulin in patients with type 2 diabetes


Authors listLinn, Thomas; Fischer, Britta; Soydan, Nedim; Eckhard, Michael; Ehl, Julia; Kunz, Clemens; Bretzel, Reinhard G.

Publication year2008

Pages3839-3846

JournalThe Journal of Clinical Endocrinology & Metabolism

Volume number93

Issue number10

ISSN0021-972X

eISSN1945-7197

Open access statusBronze

DOI Linkhttps://doi.org/10.1210/jc.2007-2871

Conference66th Annual Meeting of the American-Diabetes-Association

PublisherOxford University Press


Abstract

Aims/Hypothesis: Insulin glargine is a long-acting human insulin analog often administered at bedtime to patients with type 2 diabetes. It reduces fasting blood glucose levels more efficiently and with less nocturnal hypoglycemic events compared with human neutral protamine Hagedorn (NPH) insulin. Therefore, bedtime injections of insulin glargine and NPH insulin were compared overnight and in the morning.

Methods: In 10 type 2 diabetic patients, euglycemic clamps were performed, including [6,6 ']H-2(2) glucose, to study the rate of disappearance (Rd) and endogenous production (EGP) of glucose during the night. On separate days at bedtime (2200 h), patients received a sc injection of insulin glargine, NPH insulin, or saline in a randomized, double-blind fashion.

Results: Similar doses of both insulins had different metabolic profiles. NPH insulin had a greater effect on both Rd and EGP in the night compared with insulin glargine. By contrast, in the morning, insulin glargine was more effective, increasing Rd by 5.8 mu mol/kg(-1)center dot min(-1) (95% confidence interval 4.7-6.9) and reducing EGP -5.7 (-5.0 to -6.4) compared with NPH insulin. Nearly 80% of the glucose lowering effect in the morning was due to insulin glargine's reduction of EGP. Its injection was associated with one-third lower morning glucagon levels compared with NPH insulin (P = 0.021).

Conclusion/ Interpretation: Nocturnal variations of EGP and Rd explain the reduced incidence of hypoglycemia and lower fasting glucose levels reported for insulin glargine compared with human NPH insulin.




Citation Styles

Harvard Citation styleLinn, T., Fischer, B., Soydan, N., Eckhard, M., Ehl, J., Kunz, C., et al. (2008) Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine Hagedorn insulin in patients with type 2 diabetes, The Journal of Clinical Endocrinology & Metabolism, 93(10), pp. 3839-3846. https://doi.org/10.1210/jc.2007-2871

APA Citation styleLinn, T., Fischer, B., Soydan, N., Eckhard, M., Ehl, J., Kunz, C., & Bretzel, R. (2008). Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine Hagedorn insulin in patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 93(10), 3839-3846. https://doi.org/10.1210/jc.2007-2871



Keywords


BASAL INSULINLIPID-METABOLISMNPH INSULINSUBCUTANEOUS INJECTIONTIME-ACTION PROFILE

Last updated on 2025-10-06 at 09:45